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Sjögren's syndrome is an autoimmune disease that affects salivary gland tissue. Patients can show different degrees of phenotype that 
can vary from mild to severe systemic symptoms. So far, the etiopathogenesis of this condition is still not fully unraveled but it is 
believed that genetic and environmental factors are involved. 
The purpose is to understand the role of genetics on the appearance of the Sjögren's syndrome and describe the clinical signs that might 
alert for the presence of a patient with this condition. 
The most impacting oral manifestation is xerostomia. The role of the dental doctor in the diagnosis, treatment and oral rehabilitation of 
these patients, is crucial to ensure a good quality of life. 
 




The Sjögren's syndrome is a chronic autoimmune disorder that 
affects mainly the epithelium of the lacrimal and salivary glands. 
Clinically, its presentation can vary between relatively mild 
symptoms of xerostomia and xerophthalmia, arthralgias, fatigue 
and fibromyalgia, to more severe systemic symptoms [1]. 
This syndrome can be classified in two different forms: primary 
Sjögren's syndrome that develops as an isolated disease; or 
secondary Sjögren's syndrome associated with another 
autoimmune disease [2].  
The etiopathogenesis of the Sjögren's syndrome is not completely 
understood, and some studies report a set of immunological 
changes of infectious and/or genetic origin associated with the 
development of the autoimmune process [1]. 
The treatment of the Sjögren's syndrome involves a wide variety 
of medical specialties, such as rheumatology, dermatology, 
ophthalmology, immunology, pneumology, gynecology and 
dentistry [3]. The dental doctor plays an important role in the 
diagnosis of this syndrome, since, in most cases, is responsible 
for the detection of the first symptoms [4]. 
The main goals of this review are the characterization and 
etiology, the importance of genetics, the oral clinical 
manifestations, the diagnosis, the different treatment options, and 
the prevention of Sjögren's syndrome. 
 
1.1.  Methodology 
To carry out the present work, a bibliographic search of scientific 
articles published in indexed journals, available in the PUBmed 
database, was carried out, using the keywords Sjögren syndrome; 
Oral manifestations; Xerostomia; Autoimmune disease. The 
Boolean operator “AND” was used to establish a relationship 
between the search terms, to refine it and obtain more accurate 
results. 
The research was limited to publications in English, Portuguese 
or Spanish, starting in 2009, with available abstract. Narrative 
and systematic review articles, guidelines, observational studies, 
and clinical trials were considered. 
 
2. Characterization and etiology 
The Sjögren's syndrome is an inflammatory process that is 
present in the epithelial cells and in the exocrine glands, namely 
in the lacrimal and salivary glands, which causes characteristic 
symptoms [5]. 
This disease has an unknown etiology, affecting 0.5-1% of the 
population. Its most dominant manifestations are excessive 
weakness, xerostomia, xerophthalmia and arthritis. Taking into 
account the international criteria created in 2002, the diagnosis 
can be confirmed in the presence of 3 of the 4 groups of 
symptoms: ophthalmic manifestations (dry eye), oral 
manifestations (lesions in the salivary glands), histopathological 
or laboratory manifestations [6]. 
The Sjögren's syndrome occurs nine times more often in women 
than in men. This pathology is characterized by two moments: 
one between 20 and 30 years of age and the other in the middle 
of the fifth decade of life. It can appear as a primary condition, 
that is, as a disease without any other symptoms or as a secondary 
disease that appears simultaneously with other autoimmune 
diseases, such as rheumatoid arthritis, lupus erythematosus, 
dermatomyelitis, scleroderma, or primary liver cirrhosis. Patients 
with Sjögren's syndrome also show a tendency towards 
fibromyalgia, migraines, hypothyroidism, Raynaud's syndrome, 
and lymphomas [6, 7]. 
This syndrome has a complex nature since it is a lymphocytic 
infiltration of the exocrine glands, eliminating them, as is the case 
of decreased salivary and lacrimal flow [8]. 
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Bolstand et al. [8] stated that, although clinically the 
manifestations of the Sjögren's syndrome are complex, in almost 
all patients certain relevant aspects emerge that allow the 
diagnosis, as is the case of autoantibodies, specifically anti-
SSA/Ro and anti-SSB/La. Thus, many patients report certain 
symptoms such as dry eyes with the sensation of sand and dry 
mouth. Clinically, these patients may have ulcerations, 
infections, and impaired vision. Symptoms related to the eyes are 
usually present before those of the mouth. Dryness in other 
regions of the body, such as the nose, skin, and vagina, is also 
frequently reported [1]. 
 
3. Genetic susceptibility  
The Sjögren's syndrome is a highly complex condition, which 
seems to have a polygenic etiology, and can be associated with 
other autoimmune pathologies such as rheumatoid arthritis and 
systemic lupus erythematosus [1, 9]. Its development has 
multifactorial causes, involving besides the polygenic nature, the 
presence of environmental factors [10]. A complex interaction of 
multiple genes influenced by environmental factors contributes 
to the etiology of the Sjögren's syndrome. Nezos and Mavragani 
[11] observed a greater predisposition (seven times greater) for the 
development of autoimmune irregularities, in individuals with 
family relationship with patients with this pathology. 
The genetic contribution to the pathogenesis of this disease was 
demonstrated for the first time in the late 1970s and 1980s. The 
susceptibility to the disease was associated with the MHC (main 
histocompatibility complex) class II HLA (human leukocyte 
antigen) alleles [12]. 
HLA is a group of proteins that helps the immune system to 
distinguish the body's own proteins from proteins produced by 
invaders, such as viruses and bacteria. The HLA is the human 
version of the MHC. In humans, the MHC complex is made up 
of more than 200 genes, all close and located on chromosome 6. 
The genes of this complex are categorized into three basic 
groups: classes I, II, and III. Class II MHC in humans consists of 
6 genes: HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQB1, 
HLA-DRA and HLA-DRB1. These genes encode proteins almost 
exclusively present on the surface of certain cells of the immune 
system. 
So, concerning genetic causes, there is a clear distinction between 
the primary and secondary Sjögren's syndrome alleles. In primary 
Sjögren's syndrome the HLA-DR2 and HLA-DR3 subtypes 
appear more frequently, and in turn the HLA-DR4 subtypes are 
present in a less degree. However, these subtypes, when 
compared with individuals with secondary Sjögren's syndrome, 
do not present differences that can be considered significant [10]. 
Several genes have been the target of study and seem to be related 
to the individual's greater predisposition to the development of 
the Sjögren's syndrome, such as the gene encoding the interferon 
regulatory factor 5 (IRF5) [11, 13]. Likewise, genes implicated in 
B-cells or B-cell activating factor (BAFF) also known as B 
lymphocytes stimulator (BLyS), lymphotoxin α and β and tumor 
necrosis factor (TNF), are also considered [14]. 
IRF5 acts as a transcription factor, which means that it binds to 
specific regions of DNA and helps to control the activity of 
certain genes. Interferons control the activity of genes that help 
to block the replication of viruses and stimulate the activity of 
certain cells of the immune system, the natural killer cells. 
Certain viruses, such as the human T-cell lymphotropic virus 
type-1 (HTLV-1), cytomegalovirus (CMV) and hepatitis C virus 
(HCV), are possible factors for the development of the Sjögren's 
syndrome. HTLV-1 and in the same way CMV, or other 
retroviral components, are similar to self-antigens, which are 
etiologically part of the Sjögren's syndrome [14]. 
 
4. Manifestations in the oral cavity 
Individuals with the Sjögren's syndrome may demonstrate oral 
manifestations of the disease that result mainly from salivary 
hypofunction, including dental caries and less frequently 
secondary burning mouth syndrome, as well as fungal infection. 
Patients may also have difficulty in speaking and often report 
dysphasia [15]. 
Due to the Sjögren's syndrome the gums and oral mucosae are 
not protected, as a consequence of poor lubrication of the tissues, 
which in turn leads to the inflammation of the oral mucosa, 
appearance of erythematous mucosa, oral desquamation and 
traumatic ulcers [7]. In more serious situations, individuals may 
also lack tongue papilla [4]. 
 
4.1. Xerostomia 
One of the most uncomfortable symptoms of this syndrome is 
xerostomia, which is characterized by deprivation of saliva and 
its natural lubricating, protective and antibacterial properties in 
the oral cavity [6]. As a result of hyposalivation, the patient shows 
dry mouth, which in turn leads to difficulties in speaking, 
swallowing and chewing. Degeneration of the composition of the 
saliva is also frequent [4]. 
These patients have a significant decrease in the quantity and/or 
quality of the produced saliva. Most individuals refer to the 
sensation of dry mouth, whose prevalence is practically 100% of 
the cases [16]. Sjögren's syndrome affects the major and minor 
salivary glands, and 50% of all cases show an increase in volume 
of the parotid glands, symmetrical on both sides [17]. 
These changes can have significant repercussions on the lives of 
individuals, as they can lead to changes in the tone of voice or 
dry tongue, as well as decreased taste acuity or even the 
development of some oral diseases such as halitosis, gingivitis, 
periodontitis and dental caries [16]. Patients may also notice sticky 
lips, difficulty eating, speaking, chewing, swallowing, and 
retaining removable dental prostheses [18]. All these factors have 
a significant impact on the quality of life and well-being of 
individuals with Sjögren's syndrome, since it can be highly 
disabling and can lead to social isolation [19]. 
 
4.2. Dental caries 
Saliva contains phosphates, bicarbonates, and proteins. In 
patients with salivary hypofunction, there is a consequent 
reduction in the quality of the saliva, with dysregulation of 
salivary pH. Studies show that patients with this syndrome 
accumulate bigger amounts of cariogenic microorganisms in the 
dentition than individuals with normal salivation [15]. 
Consequently, according to Bayetto et al. [7], these patients will 
be more predisposed to the appearance of dental caries. Some 
authors report that this dental caries tends to appear in unusual 
areas, namely in places with less protection resulting from 
bacterial plaque, such as the gingival line and incisal edges [4, 8]. 
These patients have a high incidence of plaque, infections in the 
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gums and bleeding [4]. 
This increased risk of developing dental caries results from the 
irregular pH of saliva, since it does not have its buffering effect 
[4]. Thus, there is a loss of the antibacterial properties of saliva, 
giving the feeling of dry mouth, which in turn enhances the 
development of dental caries. Consequently, these patients need 
medical and dental services more frequently, and have a higher 
propensity for tooth loss, as well as the incidence of a greater 
number of restored teeth, compared to individuals who do not 
have any type of pathology [4]. 
 
4.3. Halitosis and periodontal disease 
Halitosis may have periodontal pathologies in its genesis, or 
result from cariogenic lesions, that is, infections in the oral cavity. 
In this sense, halitosis arises because of low salivary flow and 
infection, which in turn leads to bacterial putrefaction [4]. 
Periodontal disease is an infectious disease that results from 
inflammation, which can lead to the destruction of periodontal 
tissues and consequent bone loss [20]. 
Scientific evidence still does not allow to state that Sjögren's 
syndrome is a predictor for the appearance of periodontal disease. 
Although some authors refer to the predisposition of patients with 
Sjögren's syndrome to the development of periodontal disease, 
this relationship is not yet strongly corroborated in view of, for 
example, the problem of increased appearance of dental caries 
[21]. 
However, studies show that individuals with Sjögren's syndrome 
do not have a special need for follow-up regarding periodontal 
care, as they have a similar picture to healthy individuals. 
Although Sjögren's syndrome is systemic in nature, it does not in 
itself represent a greater risk of developing periodontal disease, 
although there is evidence of a 2.2-fold higher rate for the 
occurrence of periodontal disease in individuals with Sjögren's 
syndrome compared to healthy individuals [20]. 
 
4.4. Oral candidiasis 
The reduction in salivary flow contributes to the appearance of 
fungal infections such as Candida albicans. About 80% of 
individuals with Sjögren's syndrome have oral candidiasis, which 
can present as acute erythematous candidiasis or even as angular 
cheilitis. Angular cheilitis develops in dry, fissured, and 
erythematous lesions in the labial commissures [4].  
In individuals whose symptoms present with signs of dry mouth, 
the appearance of candidiasis is not caused by the development 
of thrush, but by wide erythema in the oral mucosa, leading to the 
loss of filiform papillae on the back of the tongue [2]. 
The risk of developing oral candidiasis is greater in patients using 
removable prostheses [20]. 
 
4.5. Papillary atrophy and others 
Papillary atrophy occurs in the lip and tongue, resulting in 
reduced salivary flow. In this way, the defense mechanisms of the 
oral cavity are compromised, which leads to the appearance of a 
burning sensation and atrophy [22]. 
One of the consequences of atrophy is the lingual depapilation, 
which can lead to changes in taste and the sensation of pain when 
in contact with certain foods [23]. 
There are countless injuries that can arise in individuals with 
Sjögren's syndrome after consuming rough foods. These 
traumatic injuries happen since saliva does not play its role 
correctly. Normally, saliva has a lubricating role on the oral 
mucosa, however, in these cases this does not happen due to the 
substantial decrease in its production [4, 18, 24]. 
Likewise, these patients have dry and chapped lips, and the 
tongue is dry, with fissures and a sticky touch because of the 
previously mentioned depapilation [4]. 
 
5. Diagnosis 
Regarding the diagnosis, the American-European Consensus 
Group (AECG) gathered rules of agreement among experts [25]. 
This classification comes from a more subjective correlation of 
symptoms, namely at the level of dry eyes and mouth together 
with more objective symptoms, such as hyposialia and dry 
keratoconjunctivitis [26,27]. 
According to the classification of the AECG for this syndrome to 
be diagnosed, it is necessary for the patient to present 4 to 6 
criteria, as is the case of positive or negative salivary gland 
biopsy, as well as the presence of certain antibodies that may be 
SSA/Ro or SSB/La [28]. 
However, since 2012, the Sjögren's International Collaborative 
Clinical Alliance Research Groups, and the American College of 
Rheumatology, presented other standards that differ from those 
presented by the AECG. In this new group of criteria, the 
symptoms of glandular manifestations are not considered, and 
there are no differences between the primary and secondary 
Sjögren's syndrome [29]. Individuals who were submitted to 
radiotherapy of the neck and head, as well as individuals with 
hepatitis C, sarcoidosis, amyloidosis, graft-host reaction, 
acquired immunodeficiency and individuals with Ig4-related 
pathologies are also excluded [26, 29]. 
However, the criteria for positive salivary gland biopsy are part 
of both groups, as well as the presence of SSA or SSB [28].  
The aim of these two groups is the establishment of unanimous 
criteria, aiming a more accurate diagnosis. Considering the 
complexity of this pathology and the diversity of symptoms, the 
diagnosis must involve several specialties. Therefore, the 
diagnosis involves a wide variety of dental and medical 
specialties, such as dentistry, rheumatology, dermatology, 
ophthalmology, immunology, pneumology and gynecology, due 
to the wide spectrum of glandular and extraglandular 
manifestations [3, 27]. 
According to the most recent criteria, patients with Sjögren's 
syndrome must show 2 of the following 3 items: 1) have anti-
SSA/Ro and/or Anti-SSB/La or rheumatoid factor and 
antinuclear antibody ≥ 1:320; 2) dry keratoconjunctivitis with a 
staining score ≥ 3; 3) biopsy of minor salivary glands showing 
focal lymphocytic sialodenitis with a focus with calcification > 1 
per 4 mm2 of glandular tissue [30, 31]. 
 
6. Treatment and prevention 
Currently, there are no specific treatments to cure Sjögren's 
syndrome patients. Thus, the type of therapies used focuses 
essentially on symptoms relieve, providing better well-being to 
the patient. To achieve this, drugs are used to prevent more severe 
periodontal pathologies, such as dental caries or periodontal 
disease [15]. 
Regarding local treatments, as is the case with oral or tear 
substitutes, these, although limited, allow to deal with a vast 
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number of symptoms [18]. In cases of xerophthalmia, the treatment 
involves the use of lacrimal substitutes and lubricating ointments 
during the day and at night. Evidence has shown that the use of 
pilocarpine or cyclosporine is somewhat successful, and in severe 
cases of xerophthalmia, anti-inflammatory agents can also be 
used [16, 32]. 
 
6.1. Oral cavity treatment and rehabilitation 
In oral treatment, both sugar-free chewing gums and salivary 
substitutes have helped in cases of mild to moderate xerostomia 
[7]. In cases where xerostomia is not very pronounced, pilocarpine 
and cevimeline are usually the choice used in the treatment [7, 16, 
18]. These drugs act as stimulators of the M1 and M3 receptors, 
present in the salivary glands, thus enhancing salivary secretion 
[18, 33]. These receptors are characterized by being present in the 
salivary glands, where M1 corresponds to gastric tissue and M3 
corresponds to smooth muscle/glands. When these receptors are 
stimulated, there is an increase in gastric juice (M1) and mucus 
secretion (M3), as well as an increased chance of sweating (M3) 
[34]. 
According to Margaix-Muñoz et al. [32], pilocarpine, acting as a 
cholinergic agent, is the most used with a dosage of about 5 
mg/day, working as a systemic salivary stimulator [4]. However, 
there are also other therapies, such as certain hydrogels, which 
release the pilocarpine agent more slowly in the oral cavity [4]. 
Thus, at the treatment level, both the drug side and the buco-
dental aspect, help to prevent and improve the symptoms and 
effects of xerostomia [32]. 
As previously mentioned, these patients show a higher incidence 
of dental caries and consequently greater tooth loss due to tooth 
decay. Prevention is a key point, but when it is too late, 
removable dentures are an alternative. However, patients with 
xerostomia have reduced retention and therefore low acceptance. 
The use of prostheses can lead to dental abrasions, stains, 
ulceration, irritation, and pain in the mucous membranes. Dental 
implants appear to be an ideal treatment alternative, although 
studies are still not conclusive. In some cases, patients with 
Sjögren's syndrome need corticosteroids to control symptoms, 
which are a contraindication for the use of dental implants [20]. 
The treatment of oral candidiasis involves the use of topical 
antifungals such as nystatin, clotrimazole or miconazole. 
Sometimes chlorhexidine is also recommended. Treatment must 
be carried out for at least 2-3 weeks [20]. 
Regarding extra glandular symptoms, although there is no 
specific treatment, certain corticosteroids and 
immunomodulating agents are used [16]. 
However, there are other aspects of treatment and rehabilitation 
of the oral cavity, such as the constant water intake [7]. 
Genetic studies in complex diseases allow the identification of 
genetic variants that contribute to their susceptibility, providing 
important information about the pathogenesis and hopes for 
future gene therapy. Experimental animal models, genetically 
and environmentally controlled, are used to study hereditary 
factors [9]. 
 
6.2. Prevention of symptoms in the oral cavity 
There are certain behaviors that should be avoided in patients 
with Sjögren's syndrome, such as tobacco and alcohol 
consumption, and others that must be meticulously followed, 
such as correct and regular oral hygiene [4]. 
It is important to alert these patients to decrease their 
consumption of foods and drinks high in sugar and carbonated 
drinks. The prostheses must be regularly disinfected, and their 
use during the night should be avoided [20]. 
In patients with Sjögren's syndrome, the prevention of dental 
caries is imperative, by chemically controlling the oral 
microbiota using chlorhexidine, xylitol, and fluorine [20]. Fluoride 
present in oral solutions or in toothpaste can be used but can also 
be applied on gel and varnish locally by a professional. For the 
control of oral and pathogenic microbiota, the use of daily 
mouthwashes of 0.12% chlorhexidine is advised [8, 32]. 
These patients with hyposalivation should also be encouraged to 
take measures to increase the level of saliva as it is crucial to 
maintain the dentition free of caries [15]. 
The use of probiotics, such as Lactobacillus and Bifidobacterium 
spp, is a new effective strategy in the prevention of symptoms in 
Sjögren's syndrome patients. These living microorganisms have 




The Sjögren's syndrome is an autoimmune disease that affects the 
lacrimal and salivary glands. Although the genetic or 
environmental causes responsible for the development of this 
condition are being surveyed, the determination of its etiology is 
still far from unraveled [32]. 
Although the cellular and humoral autoimmune reactions are not 
completely clarified, there is evidence that points to B and T 
lymphocytes as involved in the genesis of this pathology [35, 36]. It 
is evident in the literature that several factors are involved in the 
etiology of this disease, namely of an endocrine and genetic 
nature and viral infections [3]. 
Thus, the main manifestations at the oral level in patients with 
Sjögren's syndrome occur with the presentation of difficulty in 
speech, swallowing and chewing, with a dry mouth. Patients also 
report changes in taste, as well as a burning sensation and pain in 
the salivary glands associated with food intake [15]. 
Many individuals with Sjögren's syndrome still have dry and 
cracked lips and tongue, together with caries and early occlusal 
wastage of dental structures. Furthermore, 70 to 80% of these 
patients have chronic erythematous candidiasis, which may have 
repercussions on the palate and tongue and lead to the appearance 
of fissures in the lips. There may also be a bilateral swelling that 
can last from days to months or may go through periods with 
complete remission [6, 15, 32]. 
In terms of vision, the main symptoms are xerophthalmia, with a 
sensation of itching, pain, or sand in the eyes, with visual 
sensitivity, photosensitivity, erythema and eye fatigue [32, 37]. All 
these factors converge on the possibility of the occurrence of 
destruction of the bulbar and corneal epithelium, with dilation of 
the vessels of the bulbar conjunctiva, or changes in the corneal 
image [37]. 
Since Sjögren's syndrome is a systemic pathology, there are some 
dysfunctions that should be highlighted, such as the case of 
autoimmune thyroid disease found in 45% of patients [18, 38]. In 
these cases, 50% of these individuals show symptoms of extreme 
fatigue. Although there is no concrete cause, hypothyroidism is 
referred to as frequent and can contribute to this situation [18, 38]. 
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Another fact to highlight is the higher predisposition of 
individuals with Sjögren's syndrome for the development of 
leukemias or lymphomas, being identified in about 5% of these 
patients. Likewise, they may also have renal involvement and 
neurological changes that may include either the cranial, 
peripheral nerves or even the central nervous system [18]. 
 
8. Conclusion 
The present study allowed to analyze some of the main 
characteristics of Sjögren's syndrome in the light of scientific 
contributions that have been developing over the years. The 
Sjögren's syndrome is a complex, chronic, autoimmune 
pathology with the capacity to manifest itself under different 
prisms, that is, clinically there are a variety of characteristics that 
can be indicative signs of this pathology, which thus makes the 
diagnostic process quite complex. 
The diagnosis focuses on the clinical history and uses as a 
resource some evaluation exams that are in accordance with the 
criteria instituted internationally for situations of Sjögren's 
syndrome. As already mentioned, since the clinical signs can be 
of different types, the diagnosis is hampered. Thus, the dental 
doctor should not limit his intervention to the symptoms that 
encompass his universe of activity. This is a procedure that 
covers different specialties that together facilitate early diagnosis, 
so that the treatment is carried out effectively and on time. 
The Sjögren's syndrome has no cure, so symptom relief is crucial 
to ensure the patient's well-being. Prophylaxis is also a measure 
to be taken to avoid that infectious conditions or other periodontal 
diseases develop. 
Thus, early diagnosis directly influences the quality of life of the 
individual with Sjögren's syndrome, since this in severe cases can 
be fatal because patients with Sjögren's syndrome can also 
develop other milder or severe autoimmune diseases. 
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